Data reviewed in this article demonstrate that both interferon-ß-1a (IFNß-1a) and interferon-ß-1b (IFNß-1b) show a dose-response relationship in multiple sclerosis at current clinical doses.

When the immune system does not function properly, individuals become more susceptible to infections caused by viruses, bacteria, or fungi. Researchers have demonstrated that an existing drug can ...

Given its immunomodulatory effects, vitamin D has mostly been tested as an add‑on therapy to interferon beta. The research team aimed to evaluate the safety and efficacy of vitamin D as ...

IFN-beta and IFN-omega. Type I interferons are cytokines involved in the inflammatory pathways. Between 60% and 80% of adults with SLE have an increased type I interferon gene signature ...

Medication activates immune cells The researchers then added an existing drug, interferon beta, to the monocytes in the lab. This drug is used for the treatment of multiple sclerosis (MS), where ...